Vigadrone (Vigabatrin) Patent Expiration, LOE Window & CMS Spending

Vigadrone (Vigabatrin) by Upsher-Smith La: Off-Patent Genericized (AB Competition), 8 AB generics, $70.4M 2024 CMS Part D & Medicaid spend, and $14,929 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUpsher-Smith La
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$70.4M
2024 Medicare Part D Spend$338K
2024 Medicaid Spend$70.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($14,929 intro WAC)